Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

Stryker delivered 9% organic sales growth in Q2 2026 with strength across MedSurg, Neurotechnology, and Orthopaedics, supported by expanding Mako robotics adoption. However, ongoing cybersecurity remediation costs, peripheral vascular supply disruptions, and tariff-related margin benefits complicate the outlook. The company maintains a Zacks Rank #3 (Hold) rating with shares down 21.7% year-to-date.